$PPCB
Propanc Biopharma Inc Stock $ppcb

$ppcb Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000149315223004150 Filed on February 10, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2021 Q4
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$320.2K	$533.1K	$352.7K
YoY Change	-29.13%	51.15%	57.51%
% of Gross Profit
Research & Development	$66.02K	$74.88K	$50.75K
YoY Change	30.99%	47.54%
% of Gross Profit
Depreciation & Amortization	$450.00	$422.00	$500.00
YoY Change	-8.16%	-15.6%	0.0%
% of Gross Profit
Operating Expenses	$386.2K	$608.0K	$403.5K
YoY Change	-23.09%	50.69%	47.2%
Operating Profit	-$386.2K	-$608.0K	-$403.5K
YoY Change	-23.09%	50.69%
Interest Expense	$157.2K	$98.62K	-$452.0K
YoY Change	295.99%	-121.82%	248.88%
% of Operating Profit
Other Income/Expense, Net	-$425.3K	-$6.735K	-$452.0K
YoY Change	-1171.14%	-98.51%
Pretax Income	-$811.5K	-$614.7K	-$855.4K
YoY Change	75.48%	-28.14%	111.93%
Income Tax	-$1.716K	-$129.3K	-$55.46K
% Of Pretax Income
Net Earnings	-$809.8K	-$485.4K	-$800.0K
YoY Change	75.02%	-39.32%	98.19%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00	$0.00	-$0.02
Diluted Earnings Per Share	$0.00	$0.00	-$16.20K
COMMON SHARES
Basic Shares Outstanding	1.764B shares	889.7M shares	49.37M shares
Diluted Shares Outstanding	1.924M shares	960.5K shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$93.24K	$24.48K	$73.62K
YoY Change	-30.36%	-66.75%	246.61%
Cash & Equivalents	$93.24K	$24.48K	$73.62K
Short-Term Investments
Other Short-Term Assets	$0.00	$25.21K	$5.640K
YoY Change	-100.0%	346.99%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$96.58K	$54.23K	$84.88K
YoY Change	-33.17%	-36.11%	266.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$634.00	$1.083K	$3.120K
YoY Change	-76.61%	-65.29%	-79.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.010K	$2.040K	$22.18K
YoY Change	-90.97%	-90.8%	860.17%
Total Long-Term Assets	$47.17K	$53.80K	$25.30K
YoY Change	89.05%	112.63%	45.07%
TOTAL ASSETS
Total Short-Term Assets	$96.58K	$54.23K	$84.88K
Total Long-Term Assets	$47.17K	$53.80K	$25.30K
Total Assets	$143.7K	$108.0K	$110.2K
YoY Change	-15.18%	-1.96%	171.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$918.2K	$914.5K	$920.7K
YoY Change	-5.07%	-0.67%	-9.69%
Accrued Expenses	$1.289M	$1.156M	$838.9K
YoY Change	38.76%	37.76%	-35.76%
Deferred Revenue
YoY Change
Short-Term Debt	$634.6K	$821.8K	$1.026M
YoY Change	-43.9%	-19.94%	-18.93%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.060M	$2.993M	$3.040M
YoY Change	-1.82%	-1.57%	-16.67%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$24.94K	$30.89K
YoY Change
Total Long-Term Liabilities	$24.94K	$30.89K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.060M	$2.993M	$3.040M
Total Long-Term Liabilities	$24.94K	$30.89K	$0.00
Total Liabilities	$3.085M	$3.023M	$3.040M
YoY Change	-1.02%	-0.56%	-16.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$63.88M	-$63.07M
YoY Change
Common Stock	$2.621M	$1.246M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$46.48K	$46.48K
YoY Change
Treasury Stock Shares		1.000 shares
Shareholders Equity	-$2.941M	-$2.915M	-$2.930M
YoY Change
Total Liabilities & Shareholders Equity	$143.7K	$108.0K	$110.2K
YoY Change	-15.18%	-1.96%	171.25%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2021 Q4
OPERATING ACTIVITIES
Net Income	-$809.8K	-$485.4K	-$800.0K
YoY Change	75.02%	-39.32%	98.19%
Depreciation, Depletion And Amortization	$450.00	$422.00	$500.00
YoY Change	-8.16%	-15.6%	0.0%
Cash From Operating Activities	-$192.7K	-$225.2K	-$224.3K
YoY Change	-38.66%	0.4%	-14.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	269.5K	250.0K	354.5K
YoY Change	-17.58%	-29.48%	77.25%
NET CHANGE
Cash From Operating Activities	-192.7K	-225.2K	-224.3K
Cash From Investing Activities
Cash From Financing Activities	269.5K	250.0K	354.5K
Net Change In Cash	76.76K	24.78K	130.2K
YoY Change	500.63%	-80.96%	-313.29%
FREE CASH FLOW
Cash From Operating Activities	-$192.7K	-$225.2K	-$224.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001517681
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	PPCB	Common Stock Issuable CommonStockIssuable		usd
CY2022Q4	PPCB	Subscription Receivable SubscriptionReceivable		usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2021Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2021Q4	us-gaap	Interest Income Other InterestIncomeOther		usd
	us-gaap	Interest Income Other InterestIncomeOther		usd
CY2022Q4	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable		usd
CY2021Q4	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable		usd
	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable		usd
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q3	PPCB	Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants		usd
CY2021Q3	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants DeemedDividendUponAlternateCashlessExerciseOfWarrants		usd
CY2021Q4	PPCB	Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants		usd
CY2021Q4	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants DeemedDividendUponAlternateCashlessExerciseOfWarrants		usd
CY2022Q3	PPCB	Issuance Of Common Stock For Issuable Shares IssuanceOfCommonStockForIssuableShares		usd
CY2022Q3	PPCB	Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants		usd
CY2022Q3	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants DeemedDividendUponAlternateCashlessExerciseOfWarrants		usd
CY2022Q4	PPCB	Issuance Of Common Stock For Issuable Value IssuanceOfCommonStockForIssuableValue		usd
CY2022Q4	PPCB	Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants		usd
CY2022Q4	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants DeemedDividendUponAlternateCashlessExerciseOfWarrants		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable		usd
	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	PPCB	Collection Of Subscription Receivable CollectionOfSubscriptionReceivable		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	PPCB	Common Stock Issued For Offering Cost Applied Against Proceeds Received CommonStockIssuedForOfferingCostAppliedAgainstProceedsReceived		usd
	PPCB	Debt Discounts Related To Derivative Liability DebtDiscountsRelatedToDerivativeLiability		usd
	PPCB	Debt Discounts Related To Common Stock Issued With Note Payable DebtDiscountsRelatedToCommonStockIssuedWithNotePayable		usd
	PPCB	Non Cash Warrant Grant For Settlement Of Accounts Payable NonCashWarrantGrantForSettlementOfAccountsPayable		usd
	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount		usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
CY2022Q2	PPCB	Note Payable Net Of Debt Discount NotePayableNetOfDebtDiscount		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired
CY2022Q4	PPCB	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	PPCB	Weighted Average Fair Value Of Options Granted During Period WeightedAverageFairValueOfOptionsGrantedDuringPeriod	P0Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-54878
	dei	Entity Registrant Name EntityRegistrantName	PROPANC BIOPHARMA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0662986
	dei	Entity Address Address Line1 EntityAddressAddressLine1	302
	dei	Entity Address Address Line2 EntityAddressAddressLine2	6 Butler Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Camberwell, VIC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	3124
	dei	Entity Address Country EntityAddressCountry	AU
	dei	City Area Code CityAreaCode	61-03
	dei	Local Phone Number LocalPhoneNumber	9882-0780
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1763908545	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24476	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4067	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	4543	usd
CY2022Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2342	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	25207	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8621	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	54226	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	15030	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2042	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2075	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50671	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62523	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1083	usd
CY2022Q2	PPCB	Common Stock Issuable Shares CommonStockIssuableShares	19597024	shares
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2023	usd
CY2022Q4	us-gaap	Assets Assets	108022	usd
CY2022Q2	us-gaap	Assets Assets	81651	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	914491	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	943023	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	556114	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	466115	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	59733	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	57822	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	65280	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	72404	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	633740	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	926438	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21102	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20605	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	10623	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	151262	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	30257	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	30746	usd
CY2022Q4	PPCB	Loan From Related Parties Current LoanFromRelatedPartiesCurrent	50357	usd
CY2022Q2	PPCB	Loan From Related Parties Current LoanFromRelatedPartiesCurrent	51171	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	578453	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	415799	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2992554	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3062981	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30885	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42319	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	30885	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	42319	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3023439	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3105300	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1245699501	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1245699501	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	220350921	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	220350921	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1245700	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	220351	usd
CY2022Q4	PPCB	Common Stock Issuable Shares CommonStockIssuableShares	59	shares
CY2022Q2	PPCB	Common Stock Issuable CommonStockIssuable	19597	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57696390	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57124982	usd
CY2022Q2	PPCB	Subscription Receivable SubscriptionReceivable	-23758	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1253133	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1234549	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63069163	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61557893	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1	shares
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	46477	usd
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	46477	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2915417	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3023649	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108022	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81651	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	525620	usd
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	346164	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	990752	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	777904	usd
CY2022Q4	us-gaap	Occupancy Net OccupancyNet	7506	usd
CY2021Q4	us-gaap	Occupancy Net OccupancyNet	6550	usd
	us-gaap	Occupancy Net OccupancyNet	13879	usd
	us-gaap	Occupancy Net OccupancyNet	14286	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	74878	usd
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50753	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	176203	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97307	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	608004	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	403467	usd
	us-gaap	Operating Expenses OperatingExpenses	1180834	usd
	us-gaap	Operating Expenses OperatingExpenses	889497	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-608004	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-403467	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1180834	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-889497	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	98619	usd
CY2021Q4	us-gaap	Interest Expense InterestExpense	177905	usd
	us-gaap	Interest Expense InterestExpense	261371	usd
	us-gaap	Interest Expense InterestExpense	287758	usd
CY2022Q4	us-gaap	Interest Income Other InterestIncomeOther	17	usd
	us-gaap	Interest Income Other InterestIncomeOther	19	usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	62335	usd
CY2021Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-163853	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	127508	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-167757	usd
	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable	17499	usd
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	43520	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	42910	usd
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13988	usd
	us-gaap	Depreciation Depreciation	1013	usd
CY2021Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-110215	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	22235	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1086	usd
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6735	usd
CY2021Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-451973	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-51200	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-456601	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-614739	usd
CY2021Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-855440	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1232034	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1346098	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-129321	usd
CY2021Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-55463	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-129321	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-55463	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-485418	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-799977	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1102713	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1290635	usd
CY2022Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	19322	usd
CY2021Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	93398	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	408557	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	208242	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-504740	usd
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-893375	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1511270	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1498877	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	960470651	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49373565	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	718360144	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38318783	shares
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-504740	usd
CY2021Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-893375	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1511270	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1498877	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-107812	usd
CY2021Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-7697	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	18584	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	56496	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-107812	usd
CY2021Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7697	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	18584	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	56496	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-612552	usd
CY2021Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-901072	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1492686	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1442381	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-3067573	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200186	usd
CY2021Q3	PPCB	Stock Issued During Period Value Of Common Stock For Services And Accrued Expenses StockIssuedDuringPeriodValueOfCommonStockForServicesAndAccruedExpenses	581861	usd
CY2021Q3	PPCB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	275000	usd
CY2021Q3	PPCB	Adjustments To Additional Paid In Capital Reclassification Of Premium Upon Debt Conversion AdjustmentsToAdditionalPaidInCapitalReclassificationOfPremiumUponDebtConversion	109643	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20718	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	64193	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-490658	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-2306630	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	26726	usd
CY2021Q4	PPCB	Issuance Of Common Stock For Deferred Offering Cost IssuanceOfCommonStockForDeferredOfferingCost	20000	usd
CY2021Q4	PPCB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	100000	usd
CY2021Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	16667	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20718	usd
CY2021Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-7697	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-799977	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2930193	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3023649	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48469	usd
CY2022Q3	PPCB	Stock Issued During Period Value Issuance Of Common Stock For Conversion Of Convertible Debt Conversion Fee And Accrued Interest StockIssuedDuringPeriodValueIssuanceOfCommonStockForConversionOfConvertibleDebtConversionFeeAndAccruedInterest	456939	usd
CY2022Q3	PPCB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	100000	usd
CY2022Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	133646	usd
CY2022Q3	PPCB	Adjustments To Additional Paid In Capita Stock Based Compensation In Connection With Stock Warrant Grant AdjustmentsToAdditionalPaidInCapitaStockBasedCompensationInConnectionWithStockWarrantGrant	2408	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	5551	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	126396	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-617295	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2767535	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	165691	usd
CY2022Q4	PPCB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	100000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	56811	usd
CY2022Q4	PPCB	Issuance Of Common Stock In Connection With Note Payable Value IssuanceOfCommonStockInConnectionWithNotePayableValue	37500	usd
CY2022Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	85346	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-107812	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-485418	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2915417	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1102713	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1290635	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	56811	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	133422	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	22235	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1086	usd
	us-gaap	Depreciation Depreciation	895	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	83903	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	11295	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	10858	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	127508	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-167757	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	42910	usd
	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable	17499	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2408	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	41436	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	2250	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-144711	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-245000	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2238	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1417	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16724	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5637	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9520	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-51037	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	169268	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	12882	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	97414	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-6772	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	31433	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	28264	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-9936	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-734542	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-711093	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	395750	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	414500	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	100000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24711	usd
	PPCB	Collection Of Subscription Receivable CollectionOfSubscriptionReceivable	23758	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	200000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	375000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	744219	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	789500	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10732	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-7046	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20409	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	71361	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4067	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2255	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24476	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73616	usd
	us-gaap	Interest Paid Net InterestPaidNet	1323	usd
	us-gaap	Interest Paid Net InterestPaidNet	950	usd
	PPCB	Common Stock Issued For Offering Cost Applied Against Proceeds Received CommonStockIssuedForOfferingCostAppliedAgainstProceedsReceived	20000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	218992	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	126310	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	515221	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	224662	usd
	PPCB	Debt Discounts Related To Derivative Liability DebtDiscountsRelatedToDerivativeLiability	93668	usd
	PPCB	Debt Discounts Related To Common Stock Issued With Note Payable DebtDiscountsRelatedToCommonStockIssuedWithNotePayable	37500	usd
	PPCB	Non Cash Warrant Grant For Settlement Of Accounts Payable NonCashWarrantGrantForSettlementOfAccountsPayable	5551	usd
	us-gaap	Stock Issued1 StockIssued1	448440	usd
	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1 DeemedDividendUponAlternateCashlessExerciseOfWarrants1	408557	usd
	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1 DeemedDividendUponAlternateCashlessExerciseOfWarrants1	208242	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3001500005	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10001500005	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zyDFSlvYgxG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zk2xmNG8BlDb">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.6805	pure
CY2022Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.6915	pure
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1234549	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	18584	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1253133	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	4543	usd
CY2022Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2342	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10930608062	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28633002	shares
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	74878	usd
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50753	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	176203	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97307	usd
	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-129321	usd
	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-55463	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZjrTvIHGK5e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 31.5pt 0pt 0; text-align: justify"><span id="xdx_865_za3qEGGltFhh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Reclassifications</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 31.5pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operations and relate to the presentation of accrued interest separately on the consolidated balance sheet of which $<span id="xdx_901_eus-gaap--InterestPayableCurrent_iI_c20220630_zr6WO9YwBaPi" title="Interest Payable">57,822</span> was previously included in convertible notes, net of discounts and including premiums at June 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	57822	usd
	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ abilities to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance.
	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.0499	pure
	us-gaap	Profit Loss ProfitLoss	-1102713	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-734542	usd
CY2022Q4	PPCB	Working Capital Deficit WorkingCapitalDeficit	2938328	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2915417	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63069163	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25971	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28623	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24888	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	26600	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1083	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2023	usd
CY2022Q4	us-gaap	Depreciation Depreciation	422	usd
CY2021Q4	us-gaap	Depreciation Depreciation	504	usd
	us-gaap	Depreciation Depreciation	895	usd
	us-gaap	Depreciation Depreciation	1013	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022Q2	PPCB	Number Of Preferred Stock Authorized Shares NumberOfPreferredStockAuthorizedShares	1500005	shares
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	30257	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	30746	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	125000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	52596	usd
CY2022Q4	PPCB	Note Payable Net Of Debt Discount NotePayableNetOfDebtDiscount	72404	usd
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	500	usd
CY2020Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	5248	usd
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	52629	usd
CY2021Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5221	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	83903	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	11295	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	218992	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	126310	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3001500005	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	PPCB	Number Of Preferred Stock Authorized Shares NumberOfPreferredStockAuthorizedShares	1500005	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10001500005	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24711	usd
	PPCB	Subscription Receivable Value SubscriptionReceivableValue	23758	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	218992	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	9543	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	195952	usd
CY2022Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	107409	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	106799	usd
CY2022	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	12270958	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	12270958	shares
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	200000	usd
CY2022Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	200000	usd
CY2022Q4	PPCB	Deemed Dividend DeemedDividend	19322	usd
	PPCB	Deemed Dividend DeemedDividend	408557	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	105420	shares
CY2022Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	200.27
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	3305000	shares
	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceIssued	0.01
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	5960	shares
	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised	65.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	1000	shares
	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited	2000.00
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3403460	shares
CY2022Q4	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	5.51
CY2022Q4	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	3379711	shares
CY2022Q4	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisable	5.55
	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P2Y6M29D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3403460	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3403460	shares
CY2022Q4	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	3379711	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	59	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4533
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	59	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4533
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42319	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	59	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4533
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M13D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41436	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
	PPCB	Penalty Amount PenaltyAmount	30000	usd
CY2019	PPCB	Payment For Services PaymentForServices	31754
CY2019	PPCB	Payment For Services PaymentForServices	36117	usd
CY2021	PPCB	Payment For Services PaymentForServices	28493
CY2021	PPCB	Payment For Services PaymentForServices	24043	usd
CY2020Q4	PPCB	Royalties Percentage RoyaltiesPercentage	0.02	pure
CY2022Q4	PPCB	Unreimbursed Lab Fees UnreimbursedLabFees	14135	usd
CY2022Q2	PPCB	Unreimbursed Lab Fees UnreimbursedLabFees	14364	usd
	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022Q2	PPCB	Incremental Borrowing Rate IncrementalBorrowingRate	0.08	pure
CY2022Q4	PPCB	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	66201	usd
CY2022Q2	PPCB	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	66201	usd
CY2022Q4	PPCB	Accumulated Reduction AccumulatedReduction	15530	usd
CY2022Q2	PPCB	Accumulated Reduction AccumulatedReduction	3678	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50671	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	62523	usd
CY2022Q4	PPCB	Office Lease Liability OfficeLeaseLiability	66201	usd
CY2022Q2	PPCB	Office Lease Liability OfficeLeaseLiability	66201	usd
CY2022Q4	PPCB	Reduction Of Lease Liability ReductionOfLeaseLiability	14214	usd
CY2022Q2	PPCB	Reduction Of Lease Liability ReductionOfLeaseLiability	3277	usd
CY2022Q4	PPCB	Less Office Lease Current Portion LessOfficeLeaseCurrentPortion	21102	usd
CY2022Q2	PPCB	Less Office Lease Current Portion LessOfficeLeaseCurrentPortion	20605	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30885	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	12249	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	24498	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	20415	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5175	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	51987	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M3D
	us-gaap	Payments For Rent PaymentsForRent	13879	usd
	us-gaap	Payments For Rent PaymentsForRent	14286	usd
CY2022	PPCB	Bonus Payable BonusPayable	144166	aud
CY2022	PPCB	Bonus Payable BonusPayable	99691	usd
	PPCB	Bonus Payable BonusPayable	41387	aud
	PPCB	Bonus Payable BonusPayable	26620	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	69000	aud
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	46265	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	54000	aud
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	37341	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	62500	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	40500	usd
CY2022Q4	us-gaap	Share Price SharePrice	0.0006
CY2022Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	10623	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	10623	usd
CY2022Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	151262	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	151262	usd
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	151262	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	93668	usd
	PPCB	Reduction Of Derivative Liability Upon Debt Conversion ReductionOfDerivativeLiabilityUponDebtConversion	106799	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	127508	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	10623	usd

Files In Submission

Name	View Source	Status
0001493152-23-004150-index-headers.html	Edgar Link	pending
0001493152-23-004150-index.html	Edgar Link	pending
0001493152-23-004150.txt	Edgar Link	pending
0001493152-23-004150-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ppcb-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ppcb-20221231_cal.xml	Edgar Link	unprocessable
ppcb-20221231_def.xml	Edgar Link	unprocessable
ppcb-20221231_lab.xml	Edgar Link	unprocessable
ppcb-20221231_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PPCB
Propanc Biopharma Inc Stock $ppcb

2023 Q1 Form 10-Q Financial Statement

#000149315223004150 Filed on February 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB Propanc Biopharma Inc Stock $ppcb

2023 Q1 Form 10-Q Financial Statement

#000149315223004150 Filed on February 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB
Propanc Biopharma Inc Stock $ppcb